Brief: Island Pharmaceuticals Updates On Feedback Following FDA Review Of An IND
01/02/2023 01:03
Feb 1 (Reuters) - Island Pharmaceuticals Ltd ILA.AX :
* GOT ADDITIONAL FEEDBACK FOLLOWING FDA REVIEW OF IND
APPLICATION
SUBMITTED FOR ISLA-101 PHASE 2A PEACH 1 CLINICAL TRIAL
* LETTER FROM US FDA NOTES THAT ISLAND'S IND HAD BEEN PLACED
ON
CLINICAL HOLD, AS PREVIOUSLY REPORTED
Source text for Eikon: ID:nASX4QQtg9
Further company coverage: ILA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Island Pharmaceuticals
See all newsBrief: Island Pharmaceuticals Says Pivotal Marburg Data Secured For Galidesivir FDA Pathway
Brief: Island Pharmaceuticals Posts Prelim FY Loss Attributable Of A$9.8 Million
Australia's Island Pharmaceuticals rises as company boosts Galidesivir production
Brief: Island Pharmaceuticals Boosts Galidesivir Supply As Ebola Surges
Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic